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Abstract
Parasite clearance rates are important measures of anti-malarial drug efficacy. They are particularly important in the
assessment of artemisinin resistance. The slope of the log-linear segment in the middle of the parasite clearance
curve has the least inter-individual variance and is the focus of therapeutic assessment. The factors affecting
parasite clearance are reviewed. Methods of presentation and the approaches to analysis are discussed.
Introduction
The objective of anti-malarial treatment is to cure the
patient. A decline in malaria parasitaemia is essential for
recovery from symptomatic malaria. Effective anti-
malarial drugs given in the correct doses result a rapid
decline in parasite densities. The parasite clearance time
is the most frequently quoted measure of therapeutic
response but it is an imprecise measure dependent on
the pre-treatment parasitaemia. Most anti-malarials pro-
duce fractional reductions (parasite reduction ratios;
PRR) in parasitaemia of between 100 and 10,000 per
asexual cycle [1]. The graphic plot of the parasite densi-
ties that follow the start of anti-malarial treatment is
commonly termed the parasite clearance curve (Figure
1). It is an important measure of the therapeutic
response, particularly in assessing the artemisinin deri-
vatives, which accelerate ring stage clearance. The fac-
tors which affect the parasite clearance curve are
discussed and suggestions for presentation, analysis and
interpretation are provided. Many of these factors inter-
act with each other, and several are general issues
related to parasite counting.
Factors affecting the parasite clearance curve
Frequency of sampling
In most therapeutic assessments parasite counts are
taken once daily initially, or only on days 2 and 3. This
is insufficient for definition of individual parasite clear-
ance profiles, although it is enough for therapeutic com-
parisons, particularly if sample sizes are large enough.
To characterize parasite clearance profiles adequately at
least four data points are required (i.e. counts at least
twice daily), and to define lag phases adequately counts
at ≤ 6 hour intervals are required. Counts are made
until negative (usually either 200 or 500 white cells are
counted on the thick film). Many investigators check a
further slide 12 to 24 hours later to “make sure”.
Estimating parasitaemia
Patients ill with acute falciparum malaria present with a
range of parasitaemias. These initial parasite counts are
approximately log-normally distributed. Counts vary
over four orders of magnitude from approximately 100
to 1,000,000 parasitized erythrocytes/uL blood. In falci-
parum malaria, parasitized red cells circulate freely for
only one third of the 48-hour asexual cycle. For the
remainder they are sequestered in the venules and capil-
laries [2]. The peripheral blood parasite count is there-
fore a variable underestimate of the total parasite
burden [2-4]. Parasitaemias in infections with Plasmo-
dium vivax, Plasmodium malariae,a n dPlasmodium
ovale are also approximately log-normally distributed,
but very seldom exceed 100,000/uL. The zoonosis Plas-
modium knowlesi, which has a quotidian cycle, may
reach high parasite densities in humans and can be
lethal. It is also not thought to sequester significantly.
For these infections the peripheral blood parasite counts
are an accurate reflection of the total burden. As para-
site clearance is, for the mostp a r t ,af i r s to r d e rp r o c e s s
[5] then the higher the initial parasite density the longer
counts will take to become undetectable (the parasite
clearance time) (Figure 1).
Counts at high densities (> 0.1% parasitaemia) are per-
formed as the number of parasitized red cells per 1,000
red cells with multiple infected cells counted as a single
unit [6]. As red cells are either cleared or pitted as a sin-
gle unit this is not a significant source of error [7]. The
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any medium, provided the original work is properly cited.parasite count is an estimate of the density of parasites
circulating in the blood. There are always errors in this
estimate, and these may be large at low parasite densi-
ties. These errors are both systematic and random [6].
Systematic errors are related to human error, excessive
or inadequate blood on a slide, poor slide preparation,
staining problems, the uneven spatial distribution of
parasites within the thin blood film, and parasites being
obscured or difficult to identify in thick films. Some
people count more accurately than others so there may
be both fixed and random errors associated with the
person performing the count (hence the research inves-
tigations into automated counting and quantitative PCR
methods) [8]. As thin film counts decline towards 1 per
1000 red cells the counts should switch to the thick film
(0.1% parasitaemia approximates 100 parasites per 200
white cells on a thick film). In the thick film, parasites
are counted either in a fixed volume of blood or per
100 to 1,000 (usually 200) white cells [9-13]. The fixed
volume method seems slightly less precise. There has
been debate whether to use a fixed white blood cell
count of 8,000/uL or an observed count in calculating
parasite densities, with both contributing to error
[10,14,15]. White counts vary with age so using a fixed
count leads to underestimates of parasitaemia in the
young and overestimates in the old (11,14). In routine
practice the fixed count method is more usual. In field
assessments the thick film gives counts approximately
30% lower than the corresponding thin film [16]. At
very high parasite densities estimation of parasitaemia
from a thick film (when this was the only slide taken) is
particularly inaccurate. In relation to the parasite clear-
ance curve the transition from thin to thick film might
therefore be expected to result in systematic error, but
in an evaluation of approximately 4,000 serial parasite
counts taken at ≤ 6 hourly intervals we have not found
this to be the case, and so do not apply a correction.
The change from thin to thick film, whichever method
of thick film counting is used, does not affect the slope
estimates (Stepniewska K: personal communication).
Obviously at low parasite densities, close to the limit of
detection, errors are greatest. There is often a tendency for
microscopists to search a slide before starting the count
resulting in counts of one parasite per unit number of
white cells-thereby prolonging “clearance” and skewing
the estimated slope of the linear portion of parasite clear-
ance curve (Figure 2). Sometimes this “tail” to the parasite
clearance curve is real. In some patients, particularly those
who had initially high-density parasitaemias and were trea-
ted with artemisinin derivatives, low numbers of parasites
(typically 1 per 200 to 1000 white cells) may persist for
several days. This may represent persistency of dormant
blood stages ("sleeping beauties”). Random errors are
expected at low counts as parasite numbers vary in density
even from a homogeneous sample in a Poisson distribu-
tion [17,18]. Thus errors are greatest at the beginning and
the end of the parasite clearance curve. The most robust
segment with the least inter-individual variance is in the
middle of the curve, and the slope of this segment has
therefore been the focus of assessment in therapeutic
comparisons (Figure 2).
Stage of development; schizogony
The parasite population varies in age of development
over the 48-hour cycle (24 hours for P. knowlesi,7 2
hours for P. malariae). The asexual cycle begins at mer-
ozoite entry to the erythrocyte and ends at schizont rup-
ture. Based on microscopy staging most symptomatic
infections are unimodal in age distribution, but some
may be bimodal or multimodal [4,19]. Developmental
staging by microscopy is imprecise, providing age
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Figure 1 Two P. falciparum parasite clearance curves with
identical therapeutic responses illustrating the dependence of
the parasite clearance time on pre-treatment parasite density.
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Figure 2 Sources of variance in the P. falciparum parasite
clearance curve.
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Whereas patients with severe malaria present with para-
sites at any mean age of development, in patients who
present with uncomplicated falciparum malaria, young
ring stages predominate in peripheral blood more fre-
quently than would be expected by chance, i.e. random
sampling of parasite age distributions. This well known
observation, noted frequently in textbooks of tropical
medicine, has been explained by synchronous schizog-
ony resulting in a pulse release of pro-inflammatory
cytokines, which provokes health-seeking behaviour
[20]. If schizogony leading to schizont rupture is occur-
ring at the time of presentation and start of treatment
then new parasites will be entering the circulation
rapidly as treatment is given and, if the rate and the
numbers of new parasites entering exceeds the clearance
rate, the parasite density will rise. If ingress to the circu-
lation balances egress then counts remain unchanged.
None of the available drugs prevent schizogony if
mature schizonts are present. Thus abrupt rises in para-
sitaemia may occur just after starting treatment of syn-
chronous infections [21-23]. Infections may comprise
more than one parasite genotype, although one usually
dominates, and usually derive from more than one spor-
ozoite and thus hepatic schizont. Maturation and hepa-
tic schizont rupture may not be synchronous. The
clearance curve therefore represents a weighted average
of the individual intra- host parasite populations’ stages
of development and clearances.
Stage of development; sequestration
In Plasmodium falciparum infections mature parasites
(pigment containing trophozoites and schizonts) are sel-
dom seen in the peripheral blood because they cytoad-
here to vascular endothelium and so are sequestered [2].
This process begins at the large ring stage and may be
accelerated by fever [24]. As a consequence parasitaemia
can fall abruptly in a synchronous infection simply as a
result of cytoadherence consequent upon extensive
sequestration [3]. In such cases the predominant stages
of parasite development in peripheral blood smears are
large rings (i.e. the parasites which will soon sequester
but have not yet done so) [4]. Equally, as parasites are
released from the rupture of sequestered schizonts in
falciparum malaria, parasitaemia may rise considerably,
and to a much greater extent than seen in the other
malarias which do not sequester, and are not therefore
hidden from the microscope. The predominant stages of
parasite development in peripheral blood smears are
therefore tiny rings. Reduction in fever may result in an
apparent slowing of initial parasite clearance by delaying
the onset of sequestration.
Drug effects
Most anti-malarial drugs affect predominantly the more
mature trophozoite stages of parasite development
[25,26]. This results in clearance of the circulating para-
sitized erythrocytes in the so-called benign malarias, or
in the case of falciparum malaria, death of the seques-
tered parasites [1]. As the sequestered parasites are not
seen in the peripheral blood film the consequences of
their killing on peripheral blood parasite counts are
delayed. Furthermore unless the anti-malarial achieves
therapeutic concentrations immediately (which occurs
only with parenteral artesunate) there is also a variable
delay related to drug absorption (which particularly slow
for intramuscular artemether and artemotil) or slow
intravenous infusion (required for quinine). As a result
the changes in parasitaemia that occur immediately (i.e
in the hours) after starting anti-malarial treatment are
largely those that would have happened anyway [22].
Rises in parasitaemia result from schizogony and falls
from sequestration [3]. In uncomplicated malaria para-
site counts are seldom taken more frequently than once
daily and these early fluctuations in parasitaemia may go
unnoticed. In severe malaria following treatment with
quinine, which does not affect greatly the circulating
ring stages [27], the net result in an individual patient is
that parasitaemia may, rise, fall or plateau until the
parasites begin to sequester (an interval of no more
than 12 hours) depending on the mean age and distribu-
tion of ages of the infecting parasites at presentation
[ 2 8 - 3 1 ] .A sac o n s e q u e n c et h ea v e r a g ep r o f i l ei na
patient series of parasite clearance times with quinine
treatment is a brief down-sloping plateau followed by a
log-linear fall. The sustained fall in parasitaemia results
from some ring stage killing,b u tp r e d o m i n a n t l yf r o m
the killing of sequestered parasites which cannot there-
fore mature and multiply to feed new young parasites
into the circulation. For fully sensitive parasites chloro-
quine results in faster parasite clearance, which presum-
ably reflects a broader stage-specificity of action
compared with quinine [32].
The pharmacological hallmark of the artemisinin deri-
vatives is that they clear parasitaemia more rapidly than
other drugs (Figure 3). In addition to this evident quan-
titative effect they alter the shape of the parasite clear-
ance curve qualitatively [1,33] so that little or no initial
plateau phase is evident, and parasitaemia starts to
decline in a log-linear manner almost as soon as parasi-
ticidal drug concentrations are reached. The slope of the
log-linear segment of the parasite clearance curve is
steeper with artemisinins than any other anti-malarial
drug. This is explained by the killing of ring stage para-
sites, which are then “pitted” out of their host red cells
and thereby removed from the circulation [34]. Artemi-
sinin derivatives therefore prevent these parasites from
maturing and sequestering [35]. This does not occur
with quinine, which explains the life-saving benefit of
artemisinin derivatives. The effects of artemisinin
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mated to be similar in-vivo [31]. The net result is a
more rapid decline in parasitaemia with the artemisinin
derivatives than any other anti-malarial drugs as the
overall parasite killing per asexual life cycle is the pro-
duct of the individual stage effects. The immediate rapid
decline in parasitaemia is a consistent finding in all stu-
dies of the artemisinin derivatives where frequent para-
site counts are taken (i.e. more than one count within
the first 12 hours).
Artemisinin resistance has now emerged in P. falci-
parum in Western Cambodia [36,37]. This is manifest by
marked slowing of parasite clearance. Unfortunately
there is no ex-vivo test that reliably predicts this in-vivo
phenotype so, until a marker is identified, assessments
depend on detailed measurement of parasite clearance
following observed treatment with quality assured arte-
misinin derivatives. The parasite clearance curves
assessed in Western Cambodia were closer to those fol-
lowing quinine treatment of falciparum malaria (Figure
4). Conventional in-vitro testing suggested little differ-
ence in susceptibility between sensitive and resistant
parasites [37]. This led to the suggestion that artemisinin
resistance reflects a reduction in ring stage susceptibility,
a proposition supported by mathematical modeling of
pharmacokinetic- pharmacodynamic relationships [38].
Host defences
Haemoglobinopathies and glucose - 6-phosphate dehy-
drogenase deficiency may augment to host defences
against malaria but the most important contributors are
the non-specific and the specific immune responses to
malaria. Therapeutic responses in malaria are enhanced
by immunity [39]. Drugs which are clearly ineffective in
non-immunes (usually children) may appear to be very
effective in immune adults. Self-cure is usual in endemic
areas even without anti-malarials. Antibody alone can be
used to treat malaria [40,41]. Even in low transmission
areas, with little background immunity, parasite clear-
ance rates vary substantially between individuals infected
with genetically identical parasites who receive artemisi-
nin combination treatment [42]. This presumably
reflects inter-individual differences in anti-malarial phar-
macokinetics, splenic function and other non-specific
host defences, and any acquired immunity. This remains
difficult to characterize in malaria as there are still no
good ex-vivo correlates of protective immunity [43].
Nevertheless some generalizations are possible. As
immunity increases parasite counts are lower, severe
malaria is less common, and parasite clearance is accel-
erated so the slopes of parasite clearance curves become
steeper. In endemic areas this is reflected in the differing
clinical presentations and therapeutic responses with
increasing age. Conversely as immunity declines, for
example if transmission is reduced, then parasite clear-
ance rates fall.
Presentation of data
Parasite clearance curves may be presented either as raw
data (Figure 5), or summarized in a number of ways.
The simplest is as mean and standard deviation values
on a log scale, which shows the range of parasite densi-
ties but may obscure the contributions of stage specifi-
city and sequestration. Normalization is justified if
clearance rates are independent of densities (i.e first
order kinetics and not Michaelis-Menten kinetics) (Fig-
ure 6). They generally are. However, high parasite densi-
ties are more likely in patients with little background
immunity, so in studies conducted in areas of high
transmission, a high parasitaemia may be cleared more
slowly than a low parasitaemia simply because the
patient lacks effective immunity against the particular
infecting parasites, independent of any drug effects, but
in areas of low transmission, where background immu-
nity is lower, there is no evidence that parasite clearance
within the range normally encountered in clinical trials
is “capacity limited” (i.e. is saturable). Thus, in a series
of patients normalization of parasite densities adjusts for
their variance and is a valid approach. An alternative
approach, which gives very little information about the
initial changes in parasitaemia and therefore stage speci-
ficity of drug action, is to present the cumulative pro-
portion of patients who are aparasitaemic by time
(Figure 3)
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Figure 3 The proportion of patients with falciparum malaria
remaining parasitaemic after receiving rectal artemisinins or
parenteral quinine in a series of randomized trials reviewed by
Gomes et al, with permission [47].
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Parasite clearance is usually analysed to assess the suit-
ability of new treatments or to investigate changes in
anti-malarial drug susceptibility. It is the drug effect
(pharmacodynamics; PD) that is of primary interest, so
the analysis attempts to account for the other
confounders, which are drug-independent. Drug expo-
sure (pharmacokinetics; PK) should also be assessed to
determine how much of the observed variance in para-
site clearance can be accounted for by inadequate drug
exposure. PK-PD relationships for anti-malarial drugs
are still poorly characterized, and most reported anti-
malarial drug trials do not have a PK component, often
leaving their interpretation uncertain. Parasite clearance
has been expressed in a number of ways. The parasite
clearance time ( P C T )i sm o s tw i d e l yu s e d ,b u tt h i si sa
function of the pre-treatment parasite count (Figure 1),
and it is critically dependent on the accuracy of micro-
scopy and the frequency with which blood slides are
taken. Any stage specificity of drug action is not
reflected in this variable as PCTs are typically between 1
and 3 days. This may not matter in uncomplicated
malaria but in infections with high parasitaemia and in
severe malaria the speed of initial response is the critical
determinant of outcome. The times taken for parasitae-
mia to fall by 50% (PC50)a n d9 0 %( P C 90) have been
used as alternatives, which are less affected by these
covariates, but still require extrapolation from clearance
curves [3]. The slope of the linear segment of the log
Figure 4 Normalized P. falciparum parasite clearance curves showing the fraction of initial parasitaemia versus time in patients
treated with artesunate in Western Cambodia and Western Thailand. Parasite clearance was significantly slower in Western Cambodia.
From Dondorp et al, with permission [37].
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able as it is determined from a best fit to several data
points well within the countable range, although it does
not reflect fully stage specificity of drug action. The slope
can be determined visually, using least squares regres-
sion, or by modelling. It remains to be decided what
should be the criteria for defining the top of the slope (i.
e. maximum value, or intersection of linear fit to the
initial plateau, or modelled fit), and for the lowest densi-
ties that should be included at the tail of the curve [29].
Thresholds
As parasite clearance is a function of host, parasite, and
drug factors [1,44] there will always be considerable
inter-individual variability in parasite clearance curves.
In the wake of the discovery of artemisinin resistance in
P. falciparum there has been considerable interest in
devising threshold values for in-vivo monitoring studies,
which could “rule-out” or “rule in” artemisinin resis-
tance. Based on the largest available data set of in-vivo
parasitological responses the malaria blood smear on
Day 3 (72 hours) proved a good predictor of subsequent
treatment failure and provides a simple screening mea-
sure for artemisinin resistance [45] (Figure 7). It was
concluded that if “n” patients with parasitemias <
100,000/μl are given a currently recommended three day
ACT the number with a positive day 3 smear should not
exceed (n+36)/24; artemisinin resistance was considered
highly unlikely if this proportion was less than 3%. The
inclusion of a day 3 parasite count in routine studies
provides a method for ruling out artemisinin resistance
with a defined precision. Unfortunately, this has been
misinterpreted to mean that if day 3 thresholds are
exceeded then artemisinin resistance is present. It does
not. It indicates the need for further study to character-
ize parasite clearance more accurately at the study loca-
tion. In other words, the threshold “rules out” but it
does not “rule in” artemisinin resistance. The day 3
value is also critically dependent upon precise timing of
the samples - it should be a 72-hour value. Sometimes
patients are treated in the afternoon and seen for fol-
low-up in the mornings -in which case “day 3” is < 72
hours. Sometimes inclusive reckoning is practiced in
which treatment starts on day 1, in which case day 3 is
48 hours not 72 hours.
Conclusion
The parasite clearance time is a useful measure of anti-
malarial drug effect but it is imprecise and depends
upon the initial parasitaemia. More detailed assessment
of the parasite clearance curve is needed to assess in-
vivo responses to the artemisinin derivatives. Research is
in progress to define the optimum methods and thresh-
old values, which identify artemisinin resistance. Stan-
dardization of methodologies for the assessment of anti-
malarial drug resistance is a primary objective of the
WorldWide Antimalarial Resistance Network
(WWARN) and a WWARN “parasite clearance estima-
tor” providing a standard method of analysing parasite
clearance data is now available as a freely accessible on-
line tool [46]. This should facilitate comparison of in-
vivo studies and help map the emergence and spread of
resistance.
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